Table 1.
Baseline characteristics of study cohort
| Oligoarthritis | RF- polyarthritis | RF+ polyarthritis | ERA | PsA | systemic JIA | Undifferentiated arthritis | |
|---|---|---|---|---|---|---|---|
|
Number of patients (% of all patients) |
107/266 (40.2%) | 87/266 (32.7%) | 4/266 (1.5%) | 30/266 (11.3%) | 13/266 (4.9%) | 10/266 (3.8%) | 15/266 (5.6%) |
|
Number of girls (% within category) |
82/107 (76.6%) | 70/87 (80.4%) | 3/4 (75%) | 8/30 (26.6%) | 9/13 (69.2%) | 4/10 (40.0%) | 10/15 (66.6%) |
| Age in years at diagnosis, median (range) | 5.0 (0.5–15.6) | 6.1 (1.0–16.2) | 10.9 (8.5–12.0) | 10.8 (1.4–16.1) | 10.2 (1.4–15.7) | 5.9 (0.9–13.4) | 8.1 (3.0–14.6) |
| Duration of symptoms in months, median (range) | 8.2 (0.0–57.1) | 10.4 (0.6–139.6) | 6.5 (1.0–9.7) | 12.5 (1.2–70.1) | 7.8 (2.2–14.0) | 5.2 (1.4–10.7) | 10.1 (0.4–31.2) |
| Duration between diagnosis and enrollment in days, median (range) | 42 (0–327) | 28 (0–363) | 110 (1–142) | 76 (0–363) | 62 (6–232) | 72 (7–327) | 42 (3–261) |
| cJADAS-10, median (range) | 8.45 (2–18.5) | 13.7 (1.5–27) | 8.62 (4–14.5) | 10.45 (2.5–22) | 14.3 (4–23.5) | 14.25 (2–24.5) | 11.5 (1.5–22.5) |
| Active joint count, median (range) | 1.8 (0–7)* | 9.9 (0–57) | 3 (2–5) | 3.6 (0–16) | 8.2 (0–29) | 11.4 (0–57) | 5.9 (1–31) |
| CRP in mg/l, median (range) | 6.53 (0–100) | 10.8 (0–124) | 0.57 (0–1.1) | 9.56 (0–65) | 4.8 (0–15) | 47.87 (4.7–96.8) | 17.2 (0–53) |
| Number of patients with previous medications (% within category) | |||||||
| Synthetic DMARDs | 54/107 (50.5%) | 65/87 (74.7%) | 3/4 (75%) | 14/30 (46.7%) | 8/13 (61.5%) | 7/10 (70%) | 5/15 (33.3%) |
| Systemic glucocorticoids, current | 19/107 (17.8%) | 41/87 (47.1%) | 1/4 (25%) | 6/30 (20%) | 7/13 (53.8%) | 10/10 (100%) | 3/15 (20%) |
| Systemic glucocorticoids, last 6 months before baseline | 20/107 (18.7%) | 27/87 (31.03%) | 1/4 (25%) | 7/30 (23.4%) | 6/13 (46.1%) | 7/10 (70%) | 4/15 (26.7%) |
| Intraarticular glucocorticoids, last 6 months before baseline | 62/107 (57.9%) | 47/87 (54.02%) | 1/4 (25%) | 8/30 (26.7%) | 3/13 (23.1%) | 3/10 (30%) | 6/15 (40%) |
| Biologic DMARDs |
2/107 (1.9%) ADA - 2 |
2/87 (2.3%) ETN - 2 |
0 (0.0%) |
3/30 (10%) ETN - 3 |
1/13 (7.7%) ETN - 1 |
3/10 (30.0%) ANA – 1 CAN – 1 TCZ – 1 |
1/15 (6.7%) ETN - 1 |
| Treatment naive | 27/107 (25.2%) | 7/87 (8.0%) | 12/30 (40.0%) | 3/13 (23.1%) | 5/15 (33.3%) | ||
Abbreviations: ADA adalimumab; ANA anakinra; CAN canakinumab; CRP C-reactive protein; DMARD disease-modifying antirheumatic drug; ERA enthesitis-related arthritis; ETN etanercept; JADAS juvenile arthritis disease activity score; PsA psoriatic arthritis; RF rheumatoid factor; TCZ tocilizumab
*4 patients had already developed extended oligoarthritis (≥5 affected joints) at baseline: 3 patients had 5 active joints, 1 patient had 7 active joints